Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.61 |
| ▸ | ACHE | P22303 | 8/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4375413 | 0.99 | KDM4E (0.67) | KDM4EHRH3ACHEALDH1A1ORAI1 | |
| SCHEMBL3774733 | 0.91 | KDM4E (0.57) | KDM4EHRH3ACHEALDH1A1ORAI1 | |
| SCHEMBL2828800 | 0.90 | ACHE (0.67) | KDM4EHRH3ACHEALDH1A1SMN1; SMN2 | |
| SCHEMBL13636008 | 0.86 | KDM4E (0.50) | KDM4EHRH3ACHEALDH1A1ORAI1 | |
| SCHEMBL4378928 | 0.86 | KDM4E (0.73) | KDM4EACHEALDH1A1ORAI1KMT2A | |
| SCHEMBL4380547 | 0.85 | ALDH1A1 (0.64) | KDM4EHRH3ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL4378521 | 0.85 | KDM4E (0.71) | KDM4EACHEALDH1A1ORAI1KMT2A | |
| SCHEMBL4375759 | 0.84 | ALDH1A1 (0.63) | KDM4EHRH3ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL4379135 | 0.84 | ALDH1A1 (0.73) | KDM4EACHEALDH1A1ORAI1KMT2A | |
| SCHEMBL17175749 | 0.84 | KDM4E (0.73) | KDM4EHRH3ACHEALDH1A1ORAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421071-B1 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-11-18 | — | — | EP | claimed |
| EP-1421071-B1 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20080113968-A1 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-20080113968-A1 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-20080113968-A1 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-7208497-B2 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2007-04-24 | — | — | US | disclosed |
| US-7208497-B2 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2007-04-24 | — | — | US | disclosed |
| US-7208497-B2 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2007-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113968-A1 | Substituted piperazines and diazepanes | HRH3, HRH4, HRH1 | KDM4E 1567/4885HRH3 1/4885ACHE 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.